Extended Data Table 4 Acquired genomic alterations to 1st line pyrotinib treatment

From: First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial

  1. amp, amplification; CN, copy number; del, deletion; PFS, progression-free survival.
Back to article page